Literature DB >> 1832202

Pergolide: a dopamine agonist at both D1 and D2 receptors.

R W Fuller1, J A Clemens.   

Abstract

Pergolide is a potent, direct-acting dopamine agonist used in treating Parkinson's disease. It is an agonist found recently to have high affinity for D3 receptors. The affinity of pergolide for D1 receptors is lower than for D2 receptors, and there have been some reports that it may not interact with D1 receptors in vivo at doses used to activate D2 receptors. A growing body of evidence suggests that pergolide does occupy and activate D1 receptors in vivo, although the relevance to therapeutic efficacy in Parkinson's disease needs further study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832202     DOI: 10.1016/0024-3205(91)90074-l

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Pergolide can induce soluble superoxide dismutase in rat striata.

Authors:  A Clow; T Hussain; V Glover; M Sandler; M Walker; D Dexter
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Pergolide block of the cloned Kv1.5 potassium channels.

Authors:  Imju Jeong; Bok Hee Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-05       Impact factor: 3.000

Review 3.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

4.  Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.

Authors:  R Granata; G K Wenning; J Jolkkonen; P Jenner; C D Marsden
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Authors:  A Markham; P Benfield
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 6.497

6.  Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson's disease.

Authors:  Galba Jean Beppe; Alain Bertrand Dongmo; Harquin Simplice Foyet; Nolé Tsabang; Zenovia Olteanu; Oana Cioanca; Monica Hancianu; Théophile Dimo; Lucian Hritcu
Journal:  BMC Complement Altern Med       Date:  2014-04-30       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.